Synonyms: sequanamycin 9
Comment: SEQ-9 is the orally bioavailable, advanced lead from the sequanamycins, a class of macrolide antibacterial compounds with potent activity against Mycobacterium tuberculosis [ 2]. It is one of the structures claimed in Sanofi's patent WO2014044645 [ 1].
|
|
2D Structure
|
|
Physico-chemical Properties
|
|
Hydrogen bond acceptors
|
22
|
Hydrogen bond donors
|
4
|
Rotatable bonds
|
23
|
Topological polar surface area
|
301.68
|
Molecular weight
|
1243.55
|
XLogP
|
4.33
|
No. Lipinski's rules broken
|
3
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
SMILES / InChI / InChIKey
|
|
Canonical SMILES
|
CC(C)CC(=O)O[C@@H]1[C@@H](C)[C@@H]([C@@H](C)CO[C@H]2[C@@H]([C@@H]([C@@H]([C@@H](C)O2)O)OC)OC)OC(=O)[C@H](C)[C@H]([C@H](C)[C@H]([C@@H](C)C[C@@](C)(C(=O)[C@@H]1C)OC(=O)NC(C)(C)CNS(=O)(=O)C3=CC=CC=C3)O[C@H]4[C@@H](/C(=N/OC)/C[C@@H](C)O4)O)O[C@H]5C[C@@H](C)N(C)C[C@H](C)O5
|
Isomeric SMILES
|
C[C@@H]1C[C@@H](O[C@H](CN1C)C)O[C@H]2[C@@H]([C@H]([C@H](C[C@](C(=O)[C@@H]([C@@H]([C@H]([C@H](OC(=O)[C@@H]2C)[C@@H](C)CO[C@H]3[C@@H]([C@@H]([C@@H]([C@H](O3)C)O)OC)OC)C)OC(=O)CC(C)C)C)(C)OC(=O)NC(C)(C)CNS(=O)(=O)C4=CC=CC=C4)C)O[C@H]5[C@@H](/C(=N/OC)/C[C@H](O5)C)O)C
|
InChI
|
InChI=1S/C61H102N4O20S/c1-32(2)25-45(66)81-51-39(9)50(34(4)30-77-58-54(75-18)53(74-17)47(67)42(12)80-58)83-56(70)41(11)52(82-46-26-35(5)65(16)29-37(7)78-46)38(8)49(84-57-48(68)44(64-76-19)27-36(6)79-57)33(3)28-61(15,55(69)40(51)10)85-59(71)63-60(13,14)31-62-86(72,73)43-23-21-20-22-24-43/h20-24,32-42,46-54,57-58,62,67-68H,25-31H2,1-19H3,(H,63,71)/b64-44+/t33-,34-,35+,36+,37-,38+,39-,40+,41+,42+,46-,47+,48+,49-,50+,51+,52-,53+,54+,57-,58+,61-/m0/s1
|
InChI Key
|
IXJRUHKGLMWLLP-XMRFQGNKSA-N
|
Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
|
|